Yitao Qi Selected Research

SUMO-1 Protein (SUMO Protein)

10/2021	The SUMO-specific protease SENP2 plays an essential role in the regulation of Kv7.2 and Kv7.3 potassium channels.
9/2014	Hyper-SUMOylation of the Kv7 potassium channel diminishes the M-current leading to seizures and sudden death.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yitao Qi Research Topics

Disease

4	Neoplasms (Cancer) 01/2022 - 01/2018
2	Seizures (Absence Seizure) 10/2021 - 09/2014
2	Channelopathies 01/2021 - 01/2016
2	Epilepsy (Aura) 01/2016 - 09/2014
2	Sudden Death 01/2016 - 09/2014
2	Sudden Unexpected Death in Epilepsy 01/2016 - 09/2014
1	Starvation 01/2022
1	Carcinogenesis 01/2022
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 12/2021
1	Motor Neuron Disease (Primary Lateral Sclerosis) 12/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Pathologic Processes 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Leukemia 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 12/2021 - 09/2014
3	Ion Channels (Ion Channel)IBA 01/2021 - 09/2014
2	SUMO-1 Protein (SUMO Protein)IBA 10/2021 - 09/2014
2	Peptide Hydrolases (Proteases)FDA Link 10/2021 - 09/2014
2	Potassium Channels (Potassium Channel)IBA 01/2016 - 09/2014
1	CalciumIBA 01/2022
1	CholesterolIBA 01/2022
1	UbiquitinIBA 10/2021
1	Acetylcholine (Acetylcholine Chloride)FDA Link 10/2021
1	Proto-Oncogene Proteins c-etsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2019
1	navitoclaxIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	ApigeninIBA 01/2019
1	Antimalarials (Antimalarial Agents)IBA 01/2018
1	artemisinin (artemisinine)IBA 01/2018
1	SurvivinIBA 01/2018
1	artenimol (dihydroartemisinin)IBA 01/2018
1	ezogabine (retigabine)IBA 09/2014

Therapy/Procedure

1	Therapeutics 01/2019